cvot tirzepatide Frontiers

In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT

24.08

★★★★☆4.8 (126)

ACC 26: SURPASS-CVOT

20.30

★★★★★4.9 (98)

💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What

27.31

★★★★★5.0 (157)

Tirzepatide Demonstrates Cardioprotective Effects in SURPASS-CVOT Trial

28.35

★★★★★4.7 (84)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

21.25

★★★★★4.9 (203)

Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM

27.78

★★★★★5.0 (176)

Tirzepatide CV Safety Comparable to Dulaglutide in SURPASS-CVOT | Paramesh Shamanna posted on the topic

21.59

★★★★★4.8 (132)